44 related articles for article (PubMed ID: 38457255)
1. CD2AP is a potential prognostic biomarker of renal clear cell carcinoma.
Chen C; Xu J; Zhang JX; Chen LY; Wei YA; Zhang WM; Shao PF; Xu HG
Cancer Med; 2024 Feb; 13(4):e7055. PubMed ID: 38457255
[TBL] [Abstract][Full Text] [Related]
2. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
3. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
4. [Role of CD2-associated protein and nephrin expression in multilocular cystic renal cell carcinoma].
Gong K; Zhao ZX; Lü TJ; Jin J
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(8):543-7. PubMed ID: 19567077
[TBL] [Abstract][Full Text] [Related]
5. STK4 is a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
Bai ZY; Peng LS; Li RQ; Peng X; Yang Z
Aging (Albany NY); 2023 Oct; 15(20):11286-11297. PubMed ID: 37870765
[TBL] [Abstract][Full Text] [Related]
6. Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
Ding G; Wang T; Liu S; Zhou Z; Ma J; Wu J
Front Immunol; 2023; 14():1102824. PubMed ID: 37122750
[TBL] [Abstract][Full Text] [Related]
7. The UCSC Genome Browser database: 2021 update.
Navarro Gonzalez J; Zweig AS; Speir ML; Schmelter D; Rosenbloom KR; Raney BJ; Powell CC; Nassar LR; Maulding ND; Lee CM; Lee BT; Hinrichs AS; Fyfe AC; Fernandes JD; Diekhans M; Clawson H; Casper J; Benet-Pagès A; Barber GP; Haussler D; Kuhn RM; Haeussler M; Kent WJ
Nucleic Acids Res; 2021 Jan; 49(D1):D1046-D1057. PubMed ID: 33221922
[TBL] [Abstract][Full Text] [Related]
8. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
[TBL] [Abstract][Full Text] [Related]
9. The role of CD2AP in the Pathogenesis of Alzheimer's Disease.
Tao QQ; Chen YC; Wu ZY
Aging Dis; 2019 Aug; 10(4):901-907. PubMed ID: 31440393
[TBL] [Abstract][Full Text] [Related]
10. TISIDB: an integrated repository portal for tumor-immune system interactions.
Ru B; Wong CN; Tong Y; Zhong JY; Zhong SSW; Wu WC; Chu KC; Wong CY; Lau CY; Chen I; Chan NW; Zhang J
Bioinformatics; 2019 Oct; 35(20):4200-4202. PubMed ID: 30903160
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
Atkins MB; Tannir NM
Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
[TBL] [Abstract][Full Text] [Related]
12. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.
Nagy Á; Lánczky A; Menyhárt O; Győrffy B
Sci Rep; 2018 Jun; 8(1):9227. PubMed ID: 29907753
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
